OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.
Optimizing Genomic Testing for Antibiotic Resistance
Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.
Deaths each year from bacterial infections (WHO)
Deaths annually in the us & europe from drug-resistant infections
Excess direct healthcare costs in the us from drug-resistant infections
OpGen, Inc. Announces $10 Million Private Placement Priced at the Market MORE
OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Testing Service for Native Specimens and Receives Bulk Order from Public Health Agency MORE
OpGen Reports Third Quarter 2020 Financial Results and Provides Business Update MORE
There are currently no upcoming events.
Latest Blog Posts
Performance Evaluation of Multiplex-PCR Pneumonia Panel for Diagnosis of Bacterial Co-Infections Among COVID-19 Patients MORE
A Multiplex Polymerase Chain Reaction Assay for Antibiotic Stewardship in Suspected Pneumonia MORE
New Antibiotics won’t solve the Antibiotic Resistance Crisis, but better Diagnostics could MORE